Fidelity Investments’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Fidelity Investments’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-161,983	Closed	-$1.85M	–	2836
2014 Q4	$1.85M	Buy	161,983 +40,083	+33%	+$435K	﹤0.01%	2439
2014 Q3	$1.4M	Buy	121,900 +64,633	+113%	+$987K	﹤0.01%	2486
2014 Q2	$1.11M	Hold	57,267	–	–	﹤0.01%	2491
2014 Q1	$1.03M	Buy	+57,267	New	+$940K	﹤0.01%	2468

Other funds holding CASC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fidelity Investments's CASC Position: Q1 2015 in Review

Fidelity Investments sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2015, closing a stake of 161,983 shares — an estimated $1.85M sold.

Fidelity Investments first reported a position in CASC in Q1 2014 and held it in 4 quarters. The position peaked at $1.85M in Q4 2014. 90 funds tracked by Wall St. Rank hold CASC as of Q1 2015.

Fidelity Investments reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
Fidelity Investments sold 161,983 Cascadian Therapeutics, Inc. shares in Q1 2015, an estimated $1.85M.
Fidelity Investments first reported a position in Cascadian Therapeutics, Inc. in Q1 2014 and held it in 4 quarters.
Fidelity Investments's Cascadian Therapeutics, Inc. position peaked at $1.85M in Q4 2014.
90 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2015.

Based on Fidelity Investments's 13F filing for Q1 2015, filed 14 May 2015.